drugset / Trial / NCT00563771

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

NCT00563771

Phase 4 Completed 38 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

To provide treatment opportunity to children and adolescent patients with hematologic malignancies by supplying the delayed marketed product and also to observe the efficacy and safety of rasburicase used in the treatment of hyperuricemia

Timeline

Start
2003-03
Primary completion
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasburicase Protein / enzyme biologic

Indications

No indication recorded.